DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Volume 22 (1995) Contents

NUMBERS 1 and 2, MAY–JUNE

Keynote Address

Cefotaxime in the 1990's—Appropriate Usage in a Cost Containment Environment **1**
Hartmut Lode

Microbiology

Cefotaxime—Unchanged Antibacterial Activity Over Years? **5**
Bernd Wiedemann and Helgard Dietz

The In Vitro Activity of Cefotaxime Versus Bacteria Involved in Selected Infections of Hospitalized Patients Outside of the Intensive Care Unit **13**
Gary V. Doern

Cefotaxime and Desacetylcefotaxime Antimicrobial Interactions: The Clinical Relevance of Enhanced Activity, A Review **19**
Ronald N. Jones

In-Vitro Killing of Penicillin-Susceptible, -Intermediate, and -Resistant Strains of Streptococcus Pneumoniae by Cefotaxime, Ceftriaxone, and Ceftizoxime: A Comparison of Bactericidal and Inhibitory Activity with Achievable CSF Levels **35**
Charles W. Stratton, Kenneth E. Aldridge, and Michael Gelfand

Antimicrobial Activity of Cefotaxime Against Infrequently Isolated Pathogenic Species (Unusual Pathogens) **43**
Martin G. Cormican and Ronald N. Jones

Pharmacology

Pharmacokinetics of Cefotaxime in Healthy Volunteers and Patients **49**
Kalpana B. Patel, David P. Nicolau, Charles H. Nightingale, and Richard Quintiliani

Pharmacodynamic (Kinetic) Considerations in the Treatment of Moderately Severe Infections with Cefotaxime **57**
John Turnidge

The Role of Pharmacokinetics and Pharmacodynamics in the Design of Dosage Schedules for q12h Cefotaxime Alone, and in Combination with Other Antibiotics **71**
David E. Nix and Jerome J. Schentag

Therapeutic Options for Cefotaxime in the Management of Bacterial Infections 77
Janet K. Raddatz, Beth E. Ostergaard, and John C. Rotschafer

The Pharmacokinetics of Cefotaxime in Dialysis Patients 85
K. Andrassy

Keynote Lecture #2

The Inter-Relationship Between Pharmacokinetics and Pharmacodynamics in Determining Dosage Regimens for Broad Spectrum Cephalosporins 89
William A. Craig

Pediatrics

Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in the Young 97
Gregory L. Kearns and Ronald A. Young

Cefotaxime Use in Pediatric Infections 105
Adnan S. Dajani

Cefotaxime for Treatment of Neonatal Sepsis and Meningitis 111
Carla M. Odio

Bactericidal Activity of Cefotaxime, Desacetylcefotaxime, Rifampin, and Combinations Tested at Cerebrospinal Fluid Levels Against Penicillin-Resistant Streptococcus Pneumoniae 119
Martin G. Cormican, Meredith E. Erwin, and Ronald N. Jones

Update on the Use of Cefotaxime for Pediatric Meningitis in Portugal 125
Henrique Lecour, Antonio Mota Miranda, and Jose Aguiar Nogueira

Keynote Lecture #3

The Selection of Cephalosporins for Hospital Formularies 129
Walter R. Wilson

Medicine Section

A Retrospective Analysis of the Clinical and Economic Outcomes of Twice Daily Dosing of Cefotaxime in a Canadian Tertiary Care Institution 135
Ling Yam Tin, Monique Pitre, and John M. Conly

Experience with Twice-Daily Cefotaxime in Spontaneous Bacterial Peritonitis in Cirrhosis 141
Antoni Rimola, Miguel Navasa, and Vicente Arroyo

Review and Reassessment of Dosing Schedules for Cefotaxime in Selected Medical Indications 147
Lowell S. Young

Twice-Daily Cefotaxime Versus Once-Daily Ceftriaxone in the Treatment of Nosocomial Pneumonia 155
B.P. Simmons, Michael Gelfand, J. Grogan, and B. Craft

A Prospective Evaluation of Twice-Daily Versus Thrice-Daily Cefotaxime (CTX) in the Treatment of Hospitalized Patients with Severe Pneumonia 159
Claus Keller

A Retrospective Analysis of the Efficacy of Cefotaxime Sodium Dosed Twice Daily: The Swedish Experience 163
S.O. Bergquist, L. Eriksson, S. Eriksson, N. Lonnbro, Arne Runehagen, J. Styrud, and A. Ahlquist

A Retrospective Analysis of Twice-Daily Cefotaxime Compared to Conventional Therapy for the Treatment of Infections in a USA Hospital **167**
John P. Burke, Stanley L. Pestotnik, David C. Classen, and James F. Lloyd

Cefotaxime Versus Ceftriaxone in the Treatment of Nosocomial Pneumonia **171**
P.M. Shah and W. Stille

Surgery

The Role of Cefotaxime in the Treatment of Surgical Infections **173**
Dietmar H. Wittmann

Cefotaxime and Metronidazole in Severe Intra-Abdominal Infection **183**
Charles Aprahamian, Moshe Schein, and Dietmar H. Wittmann

Cephalosporin-Metronidazole Combinations in the Management of Intra-Abdominal Infections **189**
David P. Nicolau, Kalpana B. Patel, Richard Quintiliani, and Charles H. Nightingale

Cefotaxime in the Treatment of Staphylococcal Infections: Comparison of In Vitro and In Vivo Studies **195**
Kenneth E. Aldridge

A Study of Cefotaxime Twice-Daily for the Therapy of Post-Operative Pneumonia **203**
H.P. Bruch and P. Kujath

Medical Economics

Econotherapeutics **209**
Michael K. Roark and William E. Reed

Switch Therapy in Community-Acquired Pneumonia **219**
Julio A. Ramirez

Pharmacoeconomics of Appropriate Antimicrobial Use **225**
Peter Davey

Cefotaxime and Ceftriaxone Use Evaluation in Pediatrics: Considerations of Cost Effectiveness in an Academic Medical Center **231**
Carlton K.K. Lee and D.J. Glen

Therapeutic Exchange of Cefotaxime (Claforan R) for Ceftriaxone (Rocephin): Evaluation, Implementation, and Subsequent Cost Savings at a 300-bed Community Hospital **235**
Rick D. Rawlings

A Team Approach to Hospital Formulary Replacement **239**
Jiyeun Lee, James A. Carlson, and Marvin A. Chamberlain

Summation **243**
Ronald N. Jones

NUMBER 3, JULY

Letter to the Editor

Serious Interpretive Error Among Three Commercial Systems for Susceptibility Testing of Aztreonam **249**
Steven A. Marshall and the Aztreonam Study Group

Bacteriology

Effect of Specimen Storage, Antibiotics, and Feminine Hygiene Products on the Detection of Group B Streptococcus by Culture and the STREP B OIA Test **253**
Rachel M. Ostroff and Jeffrey W. Steaffens

B-D-Glucuronidase Activity Among Prototrophic and Auxotrophic Variants of *Escherichia coli* and Other *Enterobacteriaceae* Commonly Implicated in Urinary Tract Infections **261**
John W. Tapsall and Christopher J. McIver

Viridans Streptococci Isolated from the Blood Stream: Relevance of Species Identification **267**
J.A. Jacobs, H.C. Schouten, E.E. Stobberingh and P.B. Soeters

Parasitology

Evaluation of an Enzyme-Linked Immunoassay for the Detection in Serum of Antibodies to *Entamoeba histolytica* **275**
Jon E. Rosenblatt, Lynne M. Sloan, and Jean E. Bestrom

Antimicrobial Susceptibility Studies

Evaluation of the Etest for Susceptibility Testing of Anaerobic Bacteria **279**
Jon E. Rosenblatt and Daniel R. Gustafson

Comparison of Susceptibility to Extended-Spectrum B-Lactam Antibiotics and Ciprofloxacin Among Gram-Negative Bacilli Isolated from Intensive Care Units **285**
Peter Yuk-Fong Liu, Yeu-Jun Lau, Bor-Shen Hu, Jainn-Ming Shyr, Zhi-Yuan Shi, Wen-Shih Tsai, Yu-Hui Lin, and Ching-Yu Tseng

Case Report

Rahnella aquatilis Bacteremia in an HIV Infected Intravenous Drug Abuser **293**
Guido Funke and Heini Rosner

Notes

Performance of the Gen-Probe Amplified *Mycobacterium tuberculosis* Direct Test in a Laboratory that Infrequently Isolates *Mycobacterium tuberculosis* **297**
Karen Welch, Gloria Brown, Vivian Jonas, and Mary Jane Ferraro

Comparitive in vitro Activity of Furopenem Against Aerobic Bacteria Isolated from Pediatric Patients **301**
Joel E. Mortensen and Jean H. Egleton

Book Review

The Encyclopedia of Molecular Biology **307**
J. Kendrew, E. Lawrence, Albert Balows and Ronald N. Jones

NUMBER 4, AUGUST

Bacteriology

Typing of Sequential Bacterial Isolates by Pulsed-Field Gel Electrophoresis **309**
Alan I. Hartstein, Ploenchan Chetchotisakd, Charles L. Phelps, and Ann M. LeMonte

Evaluation of Vitek and API 20S for Species Identification of Enterococci **315**
Helio S. Sader, Doug Biedenbach, and Ronald N. Jones

Detection of Group B *Streptococcus* by Immunoassay Following Enrichment in LIM-Selective Broth Medium **321**
Judith S. Heelan, Cecile Letourneau, and Dorothy Lamarche

Mycobacteriology

Evaluation of Mycobacteria Growth Indicator Tubes for Susceptibility Testing of *Mycobacterium tuberculosis* to Isoniazid and Rifampin **325**
Barbara S. Reisner, Alice M. Gatson, and Gail L. Woods

Antimicrobial Susceptibility Studies

Mechanism of Amikacin Resistance in *Pseudomonas aeruginosa* Isolates from Patients with Cystic Fibrosis **331**
James C. Hurley, George H. Miller, and Arnold L. Smith

Case Reports

Septicemia Due to *Vibrio cholerae* 0139 Bengal **337**
Ali Miraj Kahn, Manuel John Albert, Safiqul A. Sarker, Mihir K. Bhattacharya, and Abul K. Azad

Bronchoalveolar Lavage for the Diagnosis of Disseminated Toxoplasmosis in AIDS Patients **339**
Ignacio Gadea, Manuel Cuenca, Natividad Benito, Juan M. Pereda, and Francisco Soriano

Notes

Use of Nondenaturing Silver-Stained Polyacrylamide Gel Analysis of Polymerase Chain Reaction Amplification Products for the Differential Diagnosis of *Leptospira interrogans* Infection **343**
Marluce A.A. Oliveira, Otávia L. Caballero, Emmanuel Dias Neto, Matilde Cota Koury, Alvaro J. Romanha, Juçara Carvalho, Rudy A. Hartskeerl, and Andrew J.G. Simpson

Comparison of the in vitro Activity of Levofloxacin and Other Antimicrobial Agents Against Vancomycin-Susceptible and Vancomycin-Resistant *Enterococcus species* **349**
Mary K. Hayden, Marian G. Matushek, and Gordon M. Trenholme

Evaluation of S1 Chromogenic Cephalosporin β-Lactamase Disk Assay Tested Against Gram-Positive Anaerobes, Coagulase-Negative Staphylococci, *Prevotella* spp. and *Enterococcus* spp. **353**
Steven A. Marshall, Larry D. Sutton, and Ronald N. Jones

Evaluation of a PCR Assay for Detection of *Mycobacterium tuberculosis* in Clinical Specimens **357**
Martin G. Cormican, Maura Glennon, Una Ni Riain, Terry Smith, John Flynn, and Frank Gannon

Evaluation of Aerobic BACTEC 6A Non-Resin- and 16A Resin-Containing Media for the Recovery of Microorganisms Causing Peritonitis **361**
Joseph M. Blondeau, George B. Pylypchuk, Joanne E. Kappel, Richard B. Baltzan, Yvonne Yaschuk, and Allyson J. Adolph